Page 63 - Read Online

Page 10 of 10 Almeida et al. J Cancer Metastasis Treat 2021;7:57 https://dx.doi.org/10.20517/2394-4722.2021.108

Anticancer Drugs 2009;20:851-5. DOI PubMed
32. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med
2011;364:2496-506. DOI PubMed PMC
33. Nath S, Bhattacharyya J, Sarma PP, et al. The prognostic impact of epidermal growth factor receptor (EGFR) in patients with acute
myeloid leukaemia. Indian J Hematol Blood Transfus 2020;36:749-53. DOI PubMed PMC
34. Nath S, Bhattacharyya J, Chandra P, Saxena R, Sazawal S, Saikia KK. Clinicopathological significance of common genetic alterations
in patients with acute promyelocytic leukemia. Hematol Oncol Stem Cell Ther 2020;S1658-3876(20)30121. DOI PubMed
35. Chan G, Pilichowska M. Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non small-cell
lung cancer. Blood 2007;110:1079-80. DOI PubMed
36. Ryan MA, Nattamai KJ, Xing E, et al. Pharmacological inhibition of EGFR signaling enhances G-CSF-induced hematopoietic stem
cell mobilization. Nat Med 2010;16:1141-6. DOI PubMed PMC
37. Löwenberg B, van Putten W, Theobald M, et al; Dutch-Belgian Hemato-Oncology Cooperative Group; Swiss Group for Clinical
Cancer Research. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid
leukemia. N Engl J Med 2003;349:743-52. DOI PubMed
38. Konuma T, Ooi J, Uchida N, et al. Granulocyte colony-stimulating factor combined regimen in cord blood transplantation for acute
myeloid leukemia: a nationwide retrospective analysis in Japan. Haematologica 2014;99:e264-8. DOI PubMed PMC
39. Haouas H, Haouas S, Uzan G, Hafsia A. Identification of new markers discriminating between myeloid and lymphoid acute leukemia.
Hematology 2010;15:193-203. DOI PubMed
40. Vinante F, Rigo A, Papini E, Cassatella MA, Pizzolo G. Heparin-binding epidermal growth factor-like growth factor/diphtheria toxin
receptor expression by acute myeloid leukemia cells. Blood 1999;93:1715-23. PubMed
41. Mussai F, Egan S, Higginbotham-Jones J, et al. Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic
target. Blood 2015;125:2386-96. DOI PubMed PMC
42. Riese DJ 2nd, Cullum RL. Epiregulin: roles in normal physiology and cancer. Semin Cell Dev Biol 2014;28:49-56. DOI PubMed
PMC
43. Wu X, Qureshi IA, Liu H, Yin J, Qian X, Ruijie X. Epidermal growth factor in acute promyelocytic leukemia treated with retinoic
acid. Int J Hemato ;62:83-9. PubMed
44. Callegari C, Laborde NP, Buenaflor G, Nascimento CG, Brasel JA, Fisher DA. The source of urinary epidermal growth factor in
humans. Eur J Appl Physiol Occup Physiol 1988;58:26-31. DOI PubMed
45. Ramadan A, Griesenauer B, Adom D, et al. Specifically differentiated T cell subset promotes tumor immunity over fatal immunity. J
Exp Med 2017;214:3577-96. DOI PubMed PMC
46. Corrado C, Saieva L, Raimondo S, Santoro A, De Leo G, Alessandro R. Chronic myelogenous leukaemia exosomes modulate bone
marrow microenvironment through activation of epidermal growth factor receptor. J Cell Mol Med 2016;20:1829-39. DOI PubMed
PMC
47. Doan PL, Himburg HA, Helms K, et al. Epidermal growth factor regulates hematopoietic regeneration after radiation injury. Nat Med
2013;19:295-304. DOI PubMed PMC
48. Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). J Hematol Oncol 2020;13:143.
DOI PubMed PMC
49. Yewale C, Baradia D, Vhora I, Patil S, Misra A. Epidermal growth factor receptor targeting in cancer: a review of trends and
strategies. Biomaterials 2013;34:8690-707. DOI PubMed
50. Herbst RS, Sandler AB. Overview of the current status of human epidermal growth factor receptor inhibitors in lung cancer. Clin Lung
Cancer 2004;6 Suppl 1:S7-S19. DOI PubMed
51. Huang J, Meng L, Yang B, Sun S, Luo Z, Chen H. Safety profile of epidermal growth factor receptor tyrosine kinase inhibitors: a
disproportionality analysis of FDA adverse event reporting system. Sci Rep 2020;10:4803. DOI PubMed PMC
52. Pitini V, Arrigo C, Altavilla G. Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer. J
Clin Oncol 2008;26:3645-6. DOI PubMed
53. Boros K, Puissant A, Back M, et al. Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid
leukemia. Oncotarget 2015;6:25575-87. DOI PubMed PMC
54. Puissant A, Fenouille N, Alexe G, et al. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell 2014;25:226-42.
DOI PubMed PMC
55. Lainey E, Wolfromm A, Marie N, et al. Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia. Oncogene
2013;32:4331-42. DOI PubMed
56. Lainey E, Wolfromm A, Sukkurwala AQ, et al. EGFR inhibitors exacerbate differentiation and cell cycle arrest induced by retinoic
acid and vitamin D3 in acute myeloid leukemia cells. Cell Cycle 2013;12:2978-91. DOI PubMed PMC
57. Lainey E, Sébert M, Thépot S, et al. Erlotinib antagonizes ABC transporters in acute myeloid leukemia. Cell Cycle 2012;11:4079-92.
DOI PubMed PMC
58. Thepot S, Boehrer S, Seegers V, et al; Groupe Francophone des Myelodysplasies (GFM). A phase I/II trial of Erlotinib in higher risk
myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure. Leuk Res 2014;38:1430-4. DOI PubMed